menu
    • menu

    Company profile for Syros Pharmaceuticals

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Syros, we are redefining the power of small molecules to control the expression of genes. The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it can lead to disease. Because gene expression is fundamental to all cells, we believe our pioneering approach has potential to lead to better medicines for patients ...
    At Syros, we are redefining the power of small molecules to control the expression of genes. The genes expressed - turned on, off, up or down - in any given cell determine its type and function. When genes are expressed at the wrong time or in the wrong amounts, it can lead to disease. Because gene expression is fundamental to all cells, we believe our pioneering approach has potential to lead to better medicines for patients with a range of diseases that have eluded other genomics-based approaches. At the heart of all our efforts is our dedication to making a profound difference for patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Syros PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Syros Pharmaceuticals, Inc. 620 Memorial Drive Suite 300 Cambridge, MA 02139
    Telephone
    Telephone
    (617) 744-1340
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.syros.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/syros-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/syrospharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Global ChemShow

    Not Confirmed

    envelop Contact Supplier

    Global ChemShow

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rege Nephro acquires Tamibarotene assets from Syros Pharma.
    Rege Nephro acquires Tamibarotene assets from Syros Pharma.

    15 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rege-nephro-acquires-tamibarotene-related-assets-from-syros-pharmaceuticals-for-us-clinical-trials-302428431.html

    PR NEWSWIRE
    15 Apr 2025
    Share Share
    Syros To Voluntarily Delist From Nasdaq & Deregister With SEC
    Syros To Voluntarily Delist From Nasdaq & Deregister With SEC

    28 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250228459350/en

    BUSINESSWIRE
    28 Feb 2025
    Share Share
    Syros flunks phase 3 blood cancer trial, triggering loan default
    Syros flunks phase 3 blood cancer trial, triggering loan default

    14 Nov 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/syros-flunks-phase-3-blood-cancer-trial-triggering-loan-default-and-sinking-stock

    FIERCE BIOTECH
    14 Nov 2024
    Share Share
    Syros Announces Topline Data from SELECT-MDS-1 Trial in MDS
    Syros Announces Topline Data from SELECT-MDS-1 Trial in MDS

    12 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241112019957/en

    BUSINESSWIRE
    12 Nov 2024
    Share Share
    Syros To Report Q3 2024 Financial Results On Oct 31
    Syros To Report Q3 2024 Financial Results On Oct 31

    24 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241024190576/en

    BUSINESSWIRE
    24 Oct 2024
    Share Share
    Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
    Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

    27 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240827332437/en

    BUSINESSWIRE
    27 Aug 2024
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search